Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 4/20 | 0.41 |
| ▸ | KDM1A | O60341 | 4/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 3/20 | 0.37 |
| ▸ | HTR7 | P34969 | 3/20 | 0.37 |
| ▸ | CCR2 | P41597 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | HTR6 | P50406 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.36 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26806758 | 0.92 | MEN1 (0.39) | PGRKDM1AMAOAFSCN1GPR119 | |
| SCHEMBL26806726 | 0.92 | POLB (0.43) | PGRPOLBHTR6MAPTPIK3C2B | |
| SCHEMBL26806725 | 0.91 | PGR (0.43) | PGRPOLBPIK3C2BPIK3C2G | |
| SCHEMBL24310444 | 0.90 | NAT1 (0.38) | POLBMAPTPIK3C2BPIK3C2G | |
| SCHEMBL29566843 | 0.90 | NAT1 (0.38) | POLBMAPTPIK3C2BPIK3C2G | |
| SCHEMBL26806723 | 0.90 | PGR (0.39) | PGRPOLBHTR1AHTR7DRD2 | |
| SCHEMBL29567277 | 0.88 | PGR (0.42) | PGRKDM1AMAOAFSCN1GPR119 | |
| SCHEMBL26807133 | 0.88 | PGR (0.42) | PGRKDM1AMAOAFSCN1GPR119 | |
| SCHEMBL26806627 | 0.88 | CHEK1 (0.36) | GPR119POLBHTR6MAPTPIK3C2B | |
| SCHEMBL26806752 | 0.88 | NPY5R (0.39) | PGRPOLBMAPTPIK3C2BPIK3C2G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | PGR 4116/4885KDM1A 4709/4885MAOA 4480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.